Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» PRV-300
PRV-300
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
Endpoints
Thu, 09/21/17 - 08:49 am
JNJ
Provention Bio
IBD
inflammatory bowel disease
PRV-6527
Crohn's Disease
PRV-300
ulcerative colitis